Pluristem
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase I… Read more
Pluristem - Asset Resilience Ratio
Pluristem (PSTI) has an Asset Resilience Ratio of 48.26% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2021)
This chart shows how Pluristem's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Pluristem's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA38.19 Million | 48.26% |
| Total Liquid Assets | ILA38.19 Million | 48.26% |
Asset Resilience Insights
- Very High Liquidity: Pluristem maintains exceptional liquid asset reserves at 48.26% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pluristem Industry Peers by Asset Resilience Ratio
Compare Pluristem's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Macrogen Inc
KQ:038290 |
Biotechnology & Medical Research | 3.56% |
|
Panagene Inc
KQ:046210 |
Biotechnology & Medical Research | 0.14% |
|
Cell Biotech Co. Ltd
KQ:049960 |
Biotechnology & Medical Research | 54.84% |
|
Bioneer Corporation
KQ:064550 |
Biotechnology & Medical Research | 14.92% |
|
MEDIPOST Co. Ltd
KQ:078160 |
Biotechnology & Medical Research | 0.72% |
|
Biotoxtech Co. Ltd
KQ:086040 |
Biotechnology & Medical Research | 7.17% |
|
Peptron Inc
KQ:087010 |
Biotechnology & Medical Research | 57.41% |
|
Hadasit Bio
TA:HDST |
Biotechnology & Medical Research | 57.00% |
Annual Asset Resilience Ratio for Pluristem (2014–2021)
The table below shows the annual Asset Resilience Ratio data for Pluristem.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-06-30 | 36.04% | ILA33.71 Million | ILA93.54 Million | -21.21pp |
| 2020-06-30 | 57.25% | ILA37.51 Million | ILA65.53 Million | -5.35pp |
| 2019-06-30 | 62.60% | ILA19.60 Million | ILA31.31 Million | +8.49pp |
| 2018-06-30 | 54.10% | ILA21.08 Million | ILA38.96 Million | -2.91pp |
| 2017-06-30 | 57.01% | ILA21.40 Million | ILA37.53 Million | +0.45pp |
| 2016-06-30 | 56.56% | ILA25.98 Million | ILA45.94 Million | +13.40pp |
| 2015-06-30 | 43.16% | ILA29.42 Million | ILA68.16 Million | -23.59pp |
| 2014-06-30 | 66.75% | ILA49.41 Million | ILA74.02 Million | -- |